Disease Prevention

Disease prevention refers to the measures that reduce the occurrence, spread, progression and burden of disease, both before onset and after it has begun. It spans population-level action such as sanitation and health education, clinical services such as vaccination and screening, and the care that limits complications once a condition is established. The field draws on epidemiology to identify causes and risk factors, and on health policy and WHO guidance to decide which interventions to deliver, to whom, and at what cost.

Prevention matters because much of the disease burden is avoidable. Smallpox was eradicated, and many infectious diseases are now controlled through immunization, hygiene and surveillance. The growing share of noncommunicable diseases such as heart disease, cancer and diabetes has shifted attention toward modifiable risk factors and the social conditions that shape health. Prevention is therefore central to health systems, to economic decisions about resource allocation, and to global development goals.

This entry first defines prevention and its levels, then sets out the epidemiological basis for it. It next surveys the main interventions: immunization, prophylaxis, screening, health promotion, control of chronic risk factors, environmental and injury prevention, infection control, and genetic screening. It then turns to structural approaches (social determinants, policy and health systems), economic evaluation and international cooperation, and closes with the ethical debates and emerging challenges that shape the field.

Definition, aims and scope

Prevention refers to actions taken to avoid the occurrence of disease, injury or disability, or to limit their consequences before they become established. It is conventionally contrasted with treatment, which begins after a condition has appeared. The boundary is not always sharp. A screening test may detect a condition early enough that treatment prevents later disability, and the same drug may act as treatment in one patient and as prophylaxis in another. In its broad sense, prevention therefore covers any intervention aimed at a future health event, whether that event is an infection, a chronic condition, a fracture, a death, or the progression of an existing illness.

Two broad families of action are usually distinguished. Health promotion, as framed in the 1986 Ottawa Charter, aims to enable people to gain greater control over their health. In the prevention context it acts on the social and environmental conditions that shape risk across a whole society, such as housing, income, education, air quality and the food environment. Specific protection uses clinical and biomedical measures directed at particular diseases, including immunization, chemoprophylaxis, screening and the management of identified risk factors such as hypertension. The two are complementary: one addresses the conditions that generate risk, the other addresses agents or individuals at risk.

Population and high-risk approaches

A further distinction concerns who is targeted. A high-risk strategy identifies individuals with markedly elevated risk and offers them intensive counselling or treatment. A population strategy shifts the level of risk for everyone. Geoffrey Rose argued in Sick Individuals and Sick Populations (1985) that most cases of a common disease arise among people at moderate rather than extreme risk, simply because moderate-risk people are far more numerous. A small reduction in the average level of a factor such as blood pressure or cholesterol across a whole population can therefore prevent more cases than a programme confined to the highest-risk minority.

This produces what Rose described as a prevention paradox. A measure with large total benefit may give each individual only a very small absolute reduction in risk, so the cost or inconvenience borne by each person can appear disproportionate to personal gain. Population benefit and individual benefit are different quantities, and policy is best judged by the former, while advice given to a single person must acknowledge the latter. Each approach has limits. Population measures reach people who would not seek help, but they can be difficult to sustain and to evaluate. High-risk approaches are efficient per case identified but miss most cases, because most cases occur outside the high-risk group.

Relationship to public health, preventive medicine and clinical practice

Prevention sits at the intersection of several fields. Public health concerns the health of populations and pursues prevention through epidemiology, surveillance, legislation and organized programmes. Preventive medicine applies prevention to individuals and defined groups, typically through risk assessment, immunization, screening and counselling. Clinical practice delivers much prevention at the point of individual care, especially secondary and tertiary prevention, and the overlap is substantial. A physician who advises a patient to stop smoking is practising preventive medicine, while a tobacco tax that reduces smoking nationally is a public health action. Neither domain is complete alone. Population-level policy sets the conditions in which individual prevention is effective, and individual-level delivery turns policy into outcomes for patients. Much of this delivery takes place through primary-health-care.

Historical development

Early immunization: variolation and Jenner

Before the germ concept existed, people in several regions tried to prevent smallpox by deliberately exposing healthy individuals to material from patients' lesions, a practice known as variolation. From at least the 15th century, people in different parts of the world attempted to prevent illness this way. The practice reached the United Kingdom from Turkey in 1721, carried by Lady Mary Montagu. Variolation was risky, because the inoculated person was intentionally infected and could suffer a serious case.

In 1796, the English surgeon Edward Jenner tested a safer approach. He observed that dairymaids who contracted cowpox appeared immune to smallpox. He inoculated the eight-year-old James Phipps with cowpox material and later exposed him to smallpox without producing disease. Jenner called the procedure "vaccination," from the Latin word for cow. His method was not an isolated success: his vaccine was reported to prevent infection in about 95% of recipients for three to five years. Compulsory vaccination followed in England and Wales in 1853, a step that reflected how widely the procedure had been accepted after early skepticism.

Epidemiological and hygienic foundations

In 1847, Ignaz Semmelweis, working at a Vienna obstetric clinic, linked childbed fever to contact with cadavers. After he required physicians and students to wash their hands in chlorinated water and scrub under their nails, the death rate at the clinic fell from 11.4% to 2.7%. His ideas were slow to win acceptance: scientists began to support them roughly fourteen years after his death.

In 1854, John Snow investigated a cholera outbreak in Soho, London. He plotted the addresses of the dead and found that the deaths clustered around a water pump on Broad Street. After the pump's handle was removed, the outbreak largely subsided. Snow's conclusion ran against the prevailing miasma theory, which held that disease was carried by bad air, and his mapping is often cited as an early case of geographical epidemiology. Henry Whitehead later repeated the analysis and found a strong association between cholera deaths and use of the pump, although it was some years before Snow's observations were generally accepted.

Germ theory and the sanitation era

Louis Pasteur's work on microorganisms and Robert Koch's bacteriological methods established that specific microbes cause specific diseases. Koch identified the bacterium responsible for cholera in 1883, which supported Snow's theory that the organism spread through unclean water or food. From the late nineteenth century into the early twentieth, cities built sewer networks, filtered and later chlorinated public water supplies, regulated milk and food, and promoted pasteurization. These reforms reduced waterborne and foodborne infections well before most antibiotics or vaccines were available, and they remain the basis of the sanitation measures discussed below.

Post-war shift and the three-level framework

After the Second World War, infectious diseases declined as a share of deaths in wealthy countries, and attention moved toward cardiovascular disease, cancer and other chronic conditions. Preventive medicine textbooks of the 1950s, most influentially Leavell and Clark's work, organized prevention into primary, secondary and tertiary levels, a scheme that later expanded to include primordial and quaternary prevention. The most important milestone of the era was the eradication of smallpox. In 1967 the World Health Organization launched the Intensified Smallpox Eradication Programme, which combined surveillance with vaccination across more than 30 countries. The last case caused by the milder variola minor strain occurred in Somalia in 1977, and the World Health Assembly declared smallpox eradicated in 1980. Because the virus has no natural reservoir, it has since survived only in laboratories.

Levels of prevention

Preventive activity is commonly organised into levels that correspond to successive stages of a disease's development, from the emergence of risk factors to the long-term consequences of illness. The four-level scheme of primordial, primary, secondary and tertiary prevention is the most widely used.Levels of the prevention are mainly categorized as primordial, primary, secondary, and tertiary prevention. A fifth category, quaternary prevention, was added later and concerns harm produced by the health system itself. The levels are not strictly separate. A single programme can act at more than one level, and the same condition may be addressed at different levels over time.

Primordial prevention

Primordial prevention acts earliest in the causal chain. Its aim is to keep risk factors from becoming established by changing the social, economic, behavioural and environmental conditions that generate them.Primordial prevention acts early in the causal chain, to alter general social or economic circumstances that give rise to risk factors. Because it works on society rather than on individuals, its measures are typically policies and structural changes. Examples include improving sanitation to reduce exposure to infectious agents, supporting early-childhood development, and campaigns discouraging tobacco and drug use (e.g., smokefree air laws in public buildings). Economic instruments such as cigarette, soda, or other taxes also fall within this category, as do the broader policy choices discussed under taxation and legislation.

Primary prevention

Primary prevention aims to stop disease or injury before it begins, in people who do not yet have it.This is done by preventing exposures to hazards that cause disease or injury, altering unhealthy or unsafe behaviours that can lead to disease or injury, and increasing resistance to disease or injury should exposure occur. The most familiar tool is immunization, which raises protection through the immune system before exposure, alongside health education and specific protective measures such as protective equipment. The distinction from primordial prevention lies in the target: primordial prevention seeks to prevent risk factors from forming, whereas primary prevention addresses risk factors that already exist in order to prevent onset of a particular disease.

Secondary prevention

Secondary prevention relies on early detection and prompt treatment. Its purpose is to identify disease at a stage when it is either absent from symptoms or only mildly symptomatic, so that intervention can halt or slow its progression.The goal is to identify and treat conditions when they're most manageable, preventing them from progressing into something more serious. Typical examples are screening tests (like mammograms or cholesterol checks) that catch diseases early when treatment is more effective. In diabetes, for instance, screening at-risk individuals for raised blood glucose allows lifestyle changes or treatment to begin before complications develop. Definitions vary across sources. Some describe secondary prevention as reducing the impact of a disease that has already occurred,Secondary prevention aims to reduce the impact of a disease or injury that has already occurred. which blurs the boundary with tertiary prevention. Whether screening actually improves outcomes is a separate question, addressed under diagnosis and screening methodology.

Tertiary prevention

Tertiary prevention applies once a disease is established and the acute phase has been treated. Its goal is to limit lasting damage. Tertiary prevention seeks to soften the impact of the disease on the patient's function, longevity, and quality of life. Although its methods often resemble primary prevention, they are directed at patients rather than healthy people. Examples include helping a patient with heart disease to lose weight, or reducing an asthmatic patient's exposure to allergens. Rehabilitation, ongoing monitoring and supportive care are also central, particularly for chronic conditions such as cardiovascular disease, diabetes and cancer.

Quaternary prevention

Quaternary prevention is the least settled category. The term was introduced by the Belgian general practitioner Marc Jamoulle,The term was coined by the Belgian general practitioner Marc Jamoulle, and its original formulation focused on patients who felt ill without a demonstrable disease. The concept has since been broadened. In one widely cited modern formulation, it means protecting individuals from medical interventions that are likely to cause more harm than good.quaternary prevention is defined as an 'action taken to protect individuals (persons/patients) from medical interventions that are likely to cause more harm than good.' A typical case is watchful waiting: a young, healthy patient worried about a cholesterol result, with no cardiovascular risk factors, may be better served by observation than by prescribed treatment.An example of P4 could be the use of a "watchful waiting" strategy (watch and follow-up) when a young healthy patient without any cardiovascular risk or symptom worries about his cholesterol level. Other examples include avoiding unnecessary imaging in athletes. Drivers of overuse that quaternary prevention seeks to counter include defensive medicine which refers to the practice of recommending a diagnostic test or treatment that is not necessarily the best option for the patient as a means to avoid medical negligence lawsuits. Because the concept overlaps with clinical practice and shared decision-making, it is often placed within tertiary care as a safeguard, and it is sometimes described as an updated form of the old principle of avoiding harm.

Epidemiological foundations

Natural history and points of intervention

Preventive action depends on knowing how a disease develops in an individual before and after it appears. The natural history of disease is usually split into a prepathogenesis phase, when causal exposures act but no pathology yet exists, and a pathogenesis phase, when the disease process is established. Leavell and Clark's framework, first set out in the 1950s, maps the levels of prevention onto these phases. Primordial and primary measures target the earliest period, secondary measures aim at latent or presymptomatic disease, and tertiary measures address the consequences of established illness. The logic is that an intervention is most effective when it acts before irreversible damage occurs. Screening, for example, only has value if earlier detection changes the course of the disease.

Measures of frequency and association

Epidemiology quantifies disease with a small set of measures. Incidence is the number of new cases arising in a defined population during a given period, usually expressed as a rate per person-time. Prevalence is the proportion of a population that has the condition at a particular moment, so it reflects both how often cases arise and how long they last. Association between an exposure and an outcome is usually summarised as relative risk, $RR = \frac{I_e}{I_u}$, the ratio of incidence among the exposed to incidence among the unexposed. A relative risk of 1 indicates no association.

For prevention planning, the more useful figure is often the attributable fraction. Among the exposed, the fraction of cases attributable to the exposure is $AF_e = \frac{RR-1}{RR}$, which estimates the share of cases that would not have occurred had the exposure been absent. The population attributable fraction, which incorporates the proportion of the population exposed ($P_e$), is $PAF = \frac{P_e(RR-1)}{1+P_e(RR-1)}$. It shows how much disease a population-wide reduction in an exposure could avert, which can be far larger than the effect on any single exposed person when the exposure is common. These quantities are estimates, and their precision depends on sample size and on how exposure and outcome were measured.

Causal inference and bias

Observed associations do not establish that an exposure causes an outcome. In 1965, Austin Bradford Hill, who helped establish the causal link between smoking and lung cancer, proposed nine considerations for judging whether an association is causal, now known as the Bradford Hill criteria. They are strength, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment and analogy. Hill himself cautioned that these were considerations to weigh rather than a checklist, and that none was indispensable. Temporality, the requirement that exposure precede outcome, is the only one generally regarded as necessary.

The main threats to valid inference in observational work are confounding and bias. Confounding occurs when a third factor is associated with both the exposure and the outcome and distorts the apparent relationship. Unmeasured common causes remain a central obstacle, since statistical adjustment can only correct for variables that were recorded. Selection bias arises when the people studied differ systematically from the target population, and information bias arises from inaccurate measurement of exposure or outcome. Such biases can produce an association where none exists or conceal a real one.

Study designs

Cohort studies follow groups defined by exposure forward in time and compare the incidence of outcomes between them, which allows direct estimation of relative risk. They suit common exposures and are costly when outcomes are rare or slow to emerge. Case-control studies begin with people who have the outcome and matched controls without it, then compare their past exposures; because they sample by outcome, they usually estimate an odds ratio, which approximates relative risk when the disease is rare. They are efficient for rare conditions but more vulnerable to recall and selection bias.

Randomised controlled trials assign the preventive intervention by chance, which tends to balance known and unknown confounders between groups and gives the strongest evidence for efficacy. They underpin the licensing of vaccines and many chemoprophylactic drugs. Their limitations include cost, duration, the ethical difficulty of withholding a promising intervention, and selected participant groups that may not represent routine practice. Preventive effects established in trials are therefore often checked through cohort analyses and post-marketing surveillance under real-world conditions.

Immunization and vaccines

Immune mechanisms and memory

A vaccine trains the adaptive immune system without causing the disease. Every vaccine teaches the immune system to recognise a pathogen by exposing it to a specific molecular feature called an antigen. The vaccine itself does not cause disease in the person receiving it, but works by triggering an immune response as if the person were exposed to the live pathogen. The response produces antibodies that bind the antigen, and it leaves behind memory cells that persist after the initial exposure. When the real pathogen later arrives, the body recognises it, mounts an immediate antibody and cellular response, and clears the infection before the disease takes hold. Protection therefore depends on the speed and strength of this secondary response, which is why many vaccines require boosters to keep the memory pool large enough.

Vaccine types

Vaccines differ in how they present antigen to the immune system, and each platform involves a trade-off between immunogenicity and safety.

• Live attenuated vaccines use a pathogen whose virulence has been reduced. The classic methods of attenuation involve serial passage in cell culture or in non-human hosts until the pathogen loses virulence. The measles component of the MMR vaccine is an example. A live vaccine that replicates in the recipient produces immune responses similar to natural infection, including both antibody and cellular components, often after just one or two doses. Because the organism can replicate, live vaccines often confer long-lasting immunity but may not be suitable for immunocompromised individuals.
• Inactivated vaccines use viruses or bacteria that have been killed or altered. The killed or modified pathogen is unable to replicate and cause disease. Jonas Salk's 1955 polio vaccine used formaldehyde for this purpose. Multiple doses are often needed for inactivated vaccines to create a strong enough immune response.
• Subunit vaccines contain only selected antigens. Subunit vaccines typically require adjuvants, or substances that increase a vaccine's efficacy. The hepatitis B vaccine is made by having yeast cells produce one of the virus's surface proteins, which is then purified. Conjugate vaccines, a subtype, link a bacterial polysaccharide to a protein so that the immune system can respond to encapsulated bacteria.
• mRNA vaccines deliver genetic instructions rather than antigen itself. The vaccine delivers a messenger RNA transcript into the body's cells; the cells then use the RNA transcript as instructions to produce a certain protein. These proteins are typically the same as the proteins found on a pathogen's surface. Their rapid development makes them useful for vaccines that must be modified quickly in response to emerging variants.

Herd immunity thresholds

Herd immunity arises when enough people are immune that a pathogen cannot sustain transmission, which indirectly protects those who cannot be vaccinated. A common estimate for the threshold is 1 – (1/R₀), where R₀ is the basic reproduction number. For measles, with an R₀ of about 15, this gives roughly 93% immunity. Public health targets are set higher for measles, and the 95% benchmark is widely cited. At that level, people who can't get the vaccine, such as children younger than 12 months, are protected.

Average coverage is not the whole story. Outbreaks can emerge in pockets of contact networks among people with low vaccine uptake, even if the average vaccination coverage of a population is maintained beyond the herd immunity threshold. Thresholds also vary with transmissibility. Modelling for Europe found that to meet the goal of measles elimination in Europe, it is necessary to achieve percentages of two-dose measles vaccination coverage of at least 97%, and that the WHO objective of 95% would be insufficient for pathogens with higher R₀ values.

Coverage targets, schedules and milestones

Routine immunization programmes have been organised internationally since 1974, when the World Health Organization (WHO) established the Expanded Program on Immunization with the objective to promote essential vaccinations in all countries of the world. The original vaccines were BCG, DTP, polio and measles-containing vaccines, and since 2014, the hepatitis B vaccine, the Haemophilus influenzae vaccine, the pneumococcal conjugated vaccine, and the rotavirus vaccine have been included. National schedules now follow this framework, and global coverage of the third dose of diphtheria-tetanus-pertussis (DTP3) vaccine – often used as a marker of how well countries are providing routine immunization services to children – stood at 85 per cent in 2025, according to the WHO-UNICEF estimates. An estimated 13.5 million zero-dose children did not receive their first dose of DTP vaccine in 2025. Measles coverage is also below pre-pandemic levels: there are still 1.8Mn more children unvaccinated for measles than in 2019.

Elimination depends on sustained coverage. Smallpox is the only human disease eradicated through vaccination, with widespread vaccination leading to its eradication in 1980. For measles, the average national vaccination rate in the United States was below the herd immunity threshold and still declining, and national averages conceal state-level variation. Gaps in coverage can lead to resurgence even in countries that had previously eliminated the disease.

Chemoprophylaxis and post-exposure prophylaxis

Chemoprophylaxis uses drugs to prevent an infection or its consequences in people who are not yet ill. Post-exposure prophylaxis (PEP) is a shorter, event-triggered version given after a specific exposure, such as a needlestick injury, sexual contact with an infected partner, or a bite from a rabid animal. Both rely on antibiotics and other antimicrobials or antiparasitic drugs, so their benefits must be weighed against the harms they can cause. The main uses fall into a few groups, described below.

Antibiotic prophylaxis in surgery

Giving an antibiotic shortly before an operation reduces surgical site infection, mainly by ensuring that effective drug levels are present in tissue during the period when bacteria can contaminate the wound. Timing is the most studied variable. Current guidance generally asks for administration within 60 minutes before incision, with a 120-minute window for agents whose pharmacokinetics require it, such as vancomycin or fluoroquinolones. A meta-analysis of colorectal studies found that giving the drug more than 120 minutes before incision was associated with a markedly higher infection risk. A large US cohort of about 32,000 operations, by contrast, found that timing was not strongly associated with infection after adjustment, and it concluded that compliance with timing measures was not clearly linked to better outcomes. Duration matters too: most guidelines recommend stopping prophylaxis within 24 hours of surgery, and extending it adds exposure without clear benefit. Drug choice depends on the procedure; for many clean-contaminated operations, a cephalosporin is the standard agent.

Antimalarial chemoprevention

Malaria chemoprevention targets groups at high risk of severe disease, notably pregnant women and young children, and it can be given on a fixed schedule or during predictable high-transmission periods. Seasonal malaria chemoprevention (SMC) is the best-known example. In the Sahel, children aged 3–59 months receive monthly courses of sulfadoxine-pyrimethamine plus amodiaquine during the rainy season, usually for three to four cycles, with the number of cycles tied to the length of the transmission period. Trials and a meta-analysis of clinical trial data reported large reductions in clinical malaria compared with placebo, and routine programmes have also reduced cases, although coverage and adherence vary, with some studies in Ghana reporting that fewer than 40% of children completed all cycles. Concerns include resistance markers to the drug combination, the difficulty of reaching remote areas, and whether the benefits persist when the programme is scaled up. Extension to older children has been studied, and early results suggest reductions in parasite prevalence in children aged 5–9. Chemoprevention complements, rather than replaces, malaria vector control and case management.

Pre-exposure and post-exposure prophylaxis for HIV

Oral pre-exposure prophylaxis (PrEP) with tenofovir-based regimens is taken by people who are HIV-negative but at ongoing risk. Efficacy depends heavily on adherence. The first placebo-controlled trial among men who have sex with men, reported in 2010, showed a modest overall reduction in infection, but later analyses of the same trial found much stronger protection among participants who took the drug consistently. A meta-analysis of randomized trials found an 86% reduction in HIV acquisition among men who have sex with men when adherence was at least 80%, compared with about 45% when adherence was lower. In trials among heterosexual women, low adherence has been the main reason for failure, and drug levels measured in blood have shown that many participants were not taking the drug as prescribed. Strategies such as reminders, peer support and drug-level feedback have been used to improve adherence. Long-acting injectable forms are being developed to remove the need for daily pills. HIV PEP, by contrast, is a short course, usually 28 days, started as soon as possible after a possible exposure and ideally within 72 hours. It is an emergency measure, and its success similarly depends on starting promptly and completing the course.

Risks and resistance

Prophylactic drugs are given to people who are not sick, so the threshold for harm is low. Adverse effects range from gastrointestinal upset and allergic reactions to more serious events such as hepatotoxicity or kidney injury. Antibiotic exposure, even when brief and well-indicated, disturbs the normal bacterial flora and can select for resistant organisms, and it has been linked with infections such as Clostridioides difficile colitis. Broad-spectrum agents carry greater risk than narrow ones, which is why guidance favours the narrowest effective drug for the shortest useful period. For antimalarial and antiretroviral drugs, the main concern is that partial exposure may select for resistant strains, which is why programmes monitor resistance markers and prescribe regimens that maintain adequate drug levels throughout the risk period.

Screening and early detection

Criteria for a screening programme

Screening is the systematic testing of apparently well people to identify those who probably have a condition, so that they can be treated earlier. A screening test sorts people into those who probably have a disease and those who probably do not. A positive result is therefore a reason for diagnostic follow-up, not a diagnosis. The most widely cited framework is the set of ten principles that Wilson and Jungner prepared for the World Health Organization in 1968. Their core requirements include an important health problem, an understood natural history with a detectable early stage, an accepted and effective treatment that works better when started early, a suitable and acceptable test, an agreed policy on whom to treat, and a balance in which benefits outweigh physical and psychological harms and costs. Later bodies have extended this list. Subsequent sets of principles range from about five to more than twenty items, and they add programme-level requirements such as adequate health-service capacity, continuous case-finding and quality assurance. The UK National Screening Committee, for example, asks for randomized trial evidence that a programme reduces mortality or morbidity, not merely that a test detects disease. Because the 1968 wording is broad, national newborn screening panels differ considerably even when they cite the same criteria.

Test performance and the role of prevalence

A screening test is judged by its sensitivity, the proportion of people with the disease whom it correctly identifies, and its specificity, the proportion without the disease whom it correctly clears. These are properties of the test itself. Predictive values depend on the population being tested. The positive predictive value is the probability that a positive result reflects true disease, and it falls as prevalence falls. With a sensitivity and specificity of 90% each, a population prevalence of 1% gives

so most positive results are false alarms. The same test applied to a high-risk group, where prevalence is 10%, yields a PPV of about 50%. This is why age, sex, family history and other risk factors are used to target screening, and why a test that works well in a clinic can perform poorly in a general population sample.

Biases that mislead the evaluation of screening

Several biases can make a screening programme look more effective than it is. Lead-time bias arises because screening moves the moment of diagnosis earlier. If death occurs at the same time as it would have without screening, survival measured from diagnosis appears longer even though no life has been extended. Length-time bias arises because screening preferentially detects slowly progressing disease, since such tumours spend longer in the detectable preclinical phase and are more likely to be caught at a screen than fast-growing ones that cause symptoms between rounds. Lesions found this way are often less aggressive, so their patients do better regardless of screening. Overdiagnosis is an extreme form of length-time bias. It refers to detecting a condition that would never have caused symptoms or death in the person's lifetime, so that treatment brings harm without benefit. For this reason, trials assess screening by mortality from the disease rather than survival after diagnosis, and overdiagnosis estimates depend strongly on long follow-up and on how lead time is modelled.

Examples of established programmes

Cervical screening has moved from cytology, the Papanicolaou smear, toward testing for high-risk human papillomavirus (HPV), which is the necessary cause of nearly all cervical cancers. HPV testing has higher sensitivity for precancerous lesions, and its use allows longer intervals between tests, although the balance of sensitivity and specificity remains a design choice. Mammography for breast cancer has been evaluated in randomized trials showing reduced breast cancer mortality, but estimates of overdiagnosis and false-positive recalls remain debated. Blood pressure measurement is a low-cost opportunistic check that identifies hypertension before complications appear, and its value depends on follow-up, confirmatory measurement and treatment capacity rather than the test alone. Colorectal screening uses faecal occult blood tests, faecal immunochemical tests and colonoscopy, and its programmes depend heavily on the quality of follow-up colonoscopy and on participation rates. Across these examples, the usefulness of screening depends less on the test than on the pathway that follows an abnormal result, including diagnosis, treatment and the surveillance of people who are found to be negative.

Health promotion and behaviour change

Health promotion works on the knowledge, habits and social circumstances that shape disease risk. Its tools range from one-to-one education to national media campaigns and settings-based programmes, and its evidence base is strongest when messages are sustained, well targeted and paired with changes to the surrounding environment.

Health education, social marketing and mass media

Health education was long the dominant form of health promotion. The Ottawa Charter of 1986 folds it into a broader personal-skills action area, which covers information, education for health and life-skills development Health promotion supports personal and social development through providing information, education for health, and enhancing life skills. Social marketing borrows commercial methods such as audience segmentation, tailored messages and pre-testing to promote healthy choices, and mass-media campaigns are its most visible expression.

The evidence for those campaigns is mixed. A UK review of reviews, funded by the NIHR, identified 36 systematic reviews assessing the effectiveness of media campaigns, mostly smoking (12 reviews), sexual health (9) and physical activity (7 reviews). Its conclusions were that campaigns can reduce sedentary behaviour, improve sexual health and contribute to smoking cessation, that tobacco control campaigns can be cost-effective, that longer and more intensive campaigns tend to work better, and that message design and audience targeting matter Overall, the evidence is mixed but suggests that (1) campaigns can reduce sedentary behaviour, improve sexual health and contribute to smoking cessation, (2) tobacco control campaigns can be cost-effective, (3) longer and more intensive campaigns are likely to be more effective and (4) message design and targeting campaigns to particular population groups can be effective. Campaigns aimed at drinking or eating produced few positive changes, few campaigns directed at drinking or eating behaviours showed positive changes. Subgroup findings were also uneven: the same review found no consistent evidence that outcomes differ by ethnicity or socioeconomic status, so campaigns do not automatically narrow health gaps.

Behaviour change theories

Three frameworks are used most often to design and explain individual-level interventions. The health belief model emerged from a group of U.S. Public Health Service researchers in the 1950s, including Irwin Rosenstock, Godfrey Hochbaum, Stephen Kegeles and Howard Leventhal. They were investigating why people did not use preventive services such as tuberculosis screening. Its core constructs are perceived susceptibility to a threat, its perceived severity, the perceived benefits of acting and the perceived barriers to acting, with cues to action and self-efficacy added in common teaching versions. Its original purpose was explanatory rather than a guide to planned change.

Social cognitive theory, associated with Albert Bandura, treats personal factors, environmental influences and behaviour as interacting continuously. Its practical strategies include goal setting, behavioural contracting and tailored health communication, and its central construct is self-efficacy, or confidence in one's ability to carry out a behaviour. The transtheoretical model, also called the stages of change, describes readiness as moving through precontemplation, contemplation, preparation, action and maintenance. Its practical use rests on matching messages to each stage, a premise that has been disputed, and the stages are not always passed through in a linear sequence.

A cautionary point applies to all three. Evidence that interventions built on these models outperform those that are not is weak and inconsistent. Models that explain why people hold certain beliefs do not, by themselves, show that a programme built on them will change behaviour.

School-based and community-based programmes

The settings approach to health promotion rests on the premise that health is produced and experienced in everyday environments. The Ottawa Charter states that this has to be facilitated in school, home, work and community settings. A school programme can therefore combine a curriculum with changes to the school food environment, physical activity opportunities, staff practice and family involvement, rather than relying on lessons alone. The WHO describes healthy settings as holistic and multi-disciplinary method which integrates action across risk factors. The goal is to maximize disease prevention via a "whole system" approach. Its key principles include community participation, partnership, empowerment and equity.

Community-based work applies the same logic outside institutions. The Charter's community-action area aims to strengthen local people's role in setting priorities and designing strategies, so the programme is shaped by those it serves rather than delivered to them. Effects in these settings are generally assessed alongside the characteristics of the setting itself, not only the intervention content.

Individual messages and structural change

The Ottawa Charter is also a turning point in the conceptual debate. It "steered" health promotion away from the individual-focused health education models that dominated the field, towards a socio-ecological version rooted in the structural determinants of behaviour. Individual messages remain useful for raising awareness and shifting intentions, and the mass-media reviews document such effects. However, where choices are constrained by price, availability, advertising exposure or working conditions, messages alone reach their limits. Tobacco control, the most cost-effective area in the mass-media evidence, is the clearest case where messages operate alongside pricing and smoke-free rules, which are discussed elsewhere in this entry.

Chronic disease and modifiable risk factors

Most premature deaths from noncommunicable diseases (NCDs) such as cardiovascular disease, cancer, diabetes and chronic respiratory disease share a small set of behavioural and environmental determinants. The WHO "best buys" framework organises its options under four key risk factors for NCDs (tobacco, harmful use of alcohol, unhealthy diet and physical inactivity) and four disease areas (cardiovascular disease, diabetes, cancer and chronic respiratory disease). Its recommendations are described as cost-effective interventions, and the WHO estimates that roughly 60% of avoidable NCD deaths could be addressed by reducing alcohol and tobacco use, unhealthy diets and physical inactivity. Because these measures are largely population-level, they connect directly to the NCD agenda and to the creation of health-promoting environments described in health-promotion.

Tobacco cessation and smoke-free environments

Tobacco control is the most fully codified part of this field. The six MPOWER measures cover monitoring, protection from smoke, cessation help, warnings, advertising bans and taxation, and they are the six proven WHO MPOWER tobacco control measures to reduce tobacco use. By 2024, 6.1 billion people, over 75% of the world's population, were covered by at least one tobacco control measure. Smoke-free legislation is central to this coverage: 79 countries have implemented comprehensive smoke-free environments, covering one-third of the world's population. The health case rests partly on exposure among non-smokers, since around 1.3 million people die from second-hand smoke every year. Graphic warnings have expanded rapidly, with 110 countries now requiring them, up from just 9 in 2007. The WHO also estimates that, since the introduction of MPOWER in 2008, there are an estimated 300 million fewer people smoking today than there would be if prevalence had remained unchanged. Individual cessation support, including counselling and pharmacotherapy in clinical settings, complements these population measures but reaches a smaller share of smokers.

Diet, physical activity, alcohol and obesity

Dietary salt is a clear example of a population measure with a quantified target. The WHO recommends less than 5 g of salt or 2 g of sodium per day. The main levers are reformulation of processed foods, setting maximum permitted levels for the amount of salt in food, and front-of-pack labelling. Fiscal measures are also recommended: the WHO lists increasing excise taxes on tobacco, alcohol and unhealthy foods among its interventions. Alcohol policy follows a similar structure, including excise increases on alcoholic beverages, comprehensive restrictions on exposure to alcohol advertising and restrictions on the physical availability of alcohol in sales outlets. For physical inactivity, the recommended approach combines mass-media campaigns with community-based programmes and environmental support. Obesity prevention draws on the same food-environment measures, together with the design of schools, workplaces and urban spaces that make physical activity easier.

Hypertension and dyslipidaemia: population measures and clinical management

Hypertension illustrates how population prevention and clinical care must work together. In 2024, an estimated 1·4 billion people aged 30–79 years were living with hypertension worldwide, yet fewer than one in five had the condition adequately controlled. Awareness is also limited: an estimated 44% of adults with hypertension (600 million people) are unaware of their condition. The WHO's second global report identifies reliable access to affordable, quality-assured antihypertensive medicines and validated blood pressure devices as a cornerstone of effective care. Access remains uneven, as only 7 out of 25 low-income countries report that all five WHO-recommended hypertension medicines are generally available in pharmacies or primary care facilities. Programmes that integrate the WHO HEARTS package into primary care show that control can improve quickly; in one demonstration project, the Philippines has achieved 65% facility-level control. Modelling by the WHO suggests that scaling up access to simple, affordable, and effective treatment for just 50% of affected individuals could prevent 76 million deaths by 2050. Dyslipidaemia is managed on similar lines, with population salt and fat policies reducing the cholesterol and blood pressure burden, and clinical assessment of cardiovascular risk guiding statin or other lipid-lowering therapy for higher-risk individuals.

Clustering of risk factors and integrated prevention

The four main behavioural risk factors frequently coexist in the same person, so interventions that address one can produce benefits across several. Tobacco and alcohol control, dietary policy and activity promotion are often delivered through the same ministries and primary care services, which makes integrated planning efficient. The WHO has also identified interventions selected for their strong evidence and their ability to show results within five years, which are relevant to political planning cycles. Implementation, however, lags behind evidence. A review of seven Asian countries found that implementation gaps were largely due to inadequate funding; limited institutional capacity; inadequate action across different sectors; and a lack of standardized monitoring and evaluation mechanisms. Integrated prevention of NCDs therefore depends on sustained financing, cross-sector coordination and routine monitoring of risk-factor data, as well as on the primary health care system that delivers detection and treatment.

Environmental, occupational and injury prevention

Water supply, sanitation and hygiene

Water contaminated with microbes is estimated to cause roughly 505,000 diarrhoeal deaths a year, and the same risk category also carries cholera, typhoid and polio (Microbiologically contaminated drinking water can transmit diseases such as diarrhoea, cholera, dysentery, typhoid and polio and is estimated to cause approximately 505 000 diarrhoeal deaths each year.). Taken together, unsafe water, sanitation and hand hygiene are linked to about one million diarrhoeal deaths annually, and about 395,000 of these are children under five, a loss that could be avoided if these risks were addressed . Chlorination of municipal and household supplies kills the pathogens that water carries, while sewage treatment removes faecal material before effluent reaches rivers and aquifers. Upgrading to piped supplies and sewer connections with wastewater treatment is the step that most reliably reduces this mortality (Evidence suggests that improving service levels towards safely managed drinking-water or sanitation such as regulated piped water or connections to sewers with wastewater treatment can dramatically improve health by reducing diarrhoeal disease deaths.). Sanitation is also economically strong: a 2012 WHO analysis put the return at about 5.5 dollars for each dollar invested, counting lower health costs, higher productivity and fewer premature deaths .

Air quality and vector control

Outdoor air pollution was estimated to cause 4.2 million premature deaths worldwide in 2019, mostly from fine particulate matter (PM2.5), which drives cardiovascular and respiratory disease and some cancers . About 89% of these deaths occurred in low- and middle-income countries . Household air pollution from solid-fuel cooking was linked to 2.9 million deaths in 2021, and women and children, who typically handle cooking and firewood collection, bear the greatest share of the burden . Lowering annual PM2.5 concentrations to the WHO guideline of 5 μg/m³ could, by one estimate, reduce air-pollution deaths by around 70% . Control measures therefore include cleaner transport, energy-efficient buildings, cleaner power generation, industrial emission controls, better municipal waste management, and access to clean household energy .

Vector control targets the mosquitoes and other arthropods that transmit malaria and related infections. Insecticide-treated nets form a physical and chemical barrier over sleeping people and have been central to malaria control in sub-Saharan Africa. Larval source management works upstream by attacking breeding sites, using larvicides on standing water and removing or modifying containers and drains where larvae develop. It requires accurate mapping of breeding habitats and is usually used alongside adult-targeted measures such as nets rather than in place of them.

Occupational safety

Occupational prevention rests on legal instruments. Statutory exposure limits set maximum concentrations for hazardous substances such as lead, silica, asbestos and benzene, and regulations generally require employers to follow a hierarchy of controls: eliminating the hazard, substituting a safer material, using engineering measures such as ventilation or enclosure, applying administrative rules such as rotation and restricted hours, and only then relying on personal protective equipment. Occupational disease is a larger killer than workplace injury. Joint WHO and ILO analyses attribute a substantial number of deaths each year to exposures such as dust, carcinogens and long working hours, the last of which has been linked to stroke and ischaemic heart disease. Preventive effort is therefore directed as much at chronic exposures as at accidents. These measures are governed through national legislation, inspection regimes and workplace risk assessments, and their effectiveness depends heavily on enforcement in informal and small-scale sectors.

Road traffic and home injury

Road traffic crashes kill about 1.16 million people each year, and they are the leading cause of death for children and young adults aged 5 to 29 . Most of this burden falls on low- and middle-income countries, which account for 92% of the world's road fatalities despite having around 60% of the world's vehicles. More than half of road deaths involve pedestrians, cyclists and motorcyclists . WHO identifies safer road infrastructure, vehicle safety standards, post-crash care, enforcement of laws on key risks such as speeding, drink-driving and helmet and seat-belt use, and public awareness as the main effective responses . Protective equipment such as helmets, seat belts and child restraints, combined with urban planning that separates traffic from pedestrians, illustrates the shift from individual behaviour to designed environments.

Home injuries, including falls, burns, poisoning and drowning, especially affect young children and older adults. Prevention relies largely on design and product standards: smoke alarms, stair gates, fenced water hazards, safe storage of medicines and chemicals, child-resistant packaging, and hot-water temperature limits.

Infectious disease control and surveillance

Infectious disease control rests on a chain of functions: detecting unusual disease, notifying authorities, investigating the cluster, and interrupting transmission. Each step depends on the one before it, so a weak link in surveillance delays every later measure.

Notification systems and outbreak detection

Modern national systems depend on disease surveillance that is timely and sensitive enough to catch clusters early. Evaluation frameworks often judge a system by timeliness, sensitivity, stability and usefulness. Notifiable-disease lists typically combine diseases that are always reportable with an "unusual event" category that catches novel or unexplained patterns. Outbreak detection then moves into field investigation: confirming the diagnosis, defining a case, mapping person, place and time, and identifying the source and the exposure route. Epidemiologists use the same measures of frequency and association described elsewhere in this entry, applied to outbreak data in near real time. In many countries, laboratory networks and clinical reporting feed into the same chain, and gaps at the point of care, where patients first present, often determine how quickly a signal appears.

International Health Regulations

The WHO framework that governs cross-border reporting is the International Health Regulations (2005), which entered into force on 15 June 2007 and bind the states that are parties to it. Each state must establish a National IHR Focal Point, build minimum core capacities for surveillance and response at local, intermediate and national levels, and notify WHO of events that may constitute a public health emergency of international concern (PHEIC). Smallpox, wild-type poliovirus, novel influenza subtypes and SARS must always be notified; other events are notifiable when they meet specified criteria, such as serious public health impact, unusual or unexpected character, significant risk of international spread, or significant risk of travel or trade restrictions. Under the Regulations, a state must assess a potential event within 48 hours and report a notifiable event to WHO within 24 hours. The decision to declare a PHEIC rests with the Director-General, who consults an Emergency Committee. The Regulations were designed to reduce unnecessary trade and travel restrictions while enabling early warning, which is why they combine reporting duties with limits on the measures states may impose.

Contact tracing, isolation and quarantine

Contact tracing identifies people exposed to a confirmed case so that they can be advised to quarantine, and isolation separates infectious people from others. The effect depends on speed and coverage: the sooner cases are isolated and contacts are reached, the more transmission is interrupted before it spreads. Early in the COVID-19 pandemic, WHO guidance called for at least 80% of new cases' close contacts to be traced and quarantined within 72 hours of case confirmation, a target that WHO did not support with peer-reviewed citations at the time. A 2020 systematic review found that the evidence was largely observational or modelling-based. Fourteen observational studies reported consistent but very-low-certainty associations between tracing and better control. Eighteen modelling studies suggested that prompt and thorough tracing with effective quarantine could stop transmission, for example by lowering the reproduction number from 2.2 to 0.57 under assumed conditions. Other reviews found that quarantine of exposed people averted a substantial share of cases in model estimates, and that screening combined with isolation at low coverage could miss many asymptomatic infections. Automated tracing through smartphone applications had little empirical evidence of effect, while models suggested that high uptake would be needed for meaningful control. Because much of this evidence comes from models, justification for these measures rests on assumptions about feasibility, adherence and infectiousness, which vary by disease.

Hand hygiene and infection prevention in health-care settings

Health-care-associated infections (HAIs) are among the most frequent adverse events in health care. WHO estimates that about seven of every 100 patients in acute-care hospitals in high-income countries, and about 15 in low- and middle-income countries, acquire at least one HAI during a hospital stay. Health-care workers' hands are the main route of transmission, and the moments most likely to prevent transmission to patients, such as before patient contact and before aseptic procedures, are the ones most often missed. More than 20 hospital studies published between 1977 and 2008 linked better hand hygiene to lower infection rates, and multimodal improvement strategies, which combine training, reminders, feedback and institutional change, have produced more sustained gains than single interventions. Compliance remains uneven: WHO reports an average of about 60% in intensive care units up to 2018, with a marked gap between high-income countries and low-income countries. Alcohol-based handrubs are generally regarded as the preferred method in most clinical settings because of their microbiological efficacy, speed and accessibility at the point of care. Infection prevention also includes cleaning, device management, isolation precautions and safe water and sanitation in facilities, since a facility without basic water access cannot sustain hand hygiene.

Antimicrobial stewardship

Antimicrobial stewardship is a coordinated set of programmes that aim to ensure antibiotics are prescribed when needed, at the right dose and duration, and with the right agent. Its purpose is to reduce antibiotic resistance and infection-related harm, including the adverse effects of unnecessary treatment. Hospital programmes typically combine prescribing guidance, audit and feedback, and review of cultures, while national strategies add surveillance of resistance patterns and restrictions on sales of certain antibiotics. Stewardship and infection prevention are complementary: fewer unnecessary antibiotics reduce selection pressure on bacteria, and better infection control reduces the need for antibiotics in the first place.

Genetic and genomic prevention

Genetic and genomic prevention uses knowledge of inherited variation to identify disorders before they cause harm, or to estimate who is most likely to develop them. Its tools range from population-wide testing of newborns to individual risk estimates built from very large numbers of genetic variants. Each tool carries different evidence and ethical implications.

Newborn screening

Programmes that examine infants for conditions capable of causing disability or death took shape in the 1960s, and their stated aim is to detect disorders before symptoms appear. In many countries, a heel-prick blood sample is taken within the first two days of life. In a 2019–2021 programme in Iran, 138,689 neonates were tested by tandem mass spectrometry on dried blood spots, and abnormal results were referred for confirmatory testing.

The value of early detection depends on whether treatment changes the outcome. Some inborn errors of metabolism are curable, and early treatment can improve long-term results and, in some cases, allow treatment before symptoms develop. Panels nonetheless differ widely between countries. One comparison reported 17 conditions screened in the Netherlands, 13 in Denmark and 12 in Germany, while the United Kingdom screened only for phenylketonuria and medium-chain acyl-CoA dehydrogenase deficiency. Most European countries refer to WHO criteria, but apply them differently, which produces inconsistency. Screening also generates false positives that require follow-up, and every addition to a panel must be weighed against cost and the availability of treatment.

Carrier screening and preconception testing

Most people carry nonworking copies of some genes without any symptoms, because each person inherits two copies of every gene, one from each parent. For autosomal recessive conditions, a couple who both carry the same variant faces a 25% chance with each pregnancy of having an affected child, and roughly 2–3% of couples share such a carrier status. Testing is most useful before conception, when the results still leave room for choices. Those choices can include in vitro fertilisation, donor gametes, or prenatal diagnosis.

Testing may target a single condition suggested by family history, or it may be expanded to many genes regardless of ancestry or family background. Collectively, the genetic conditions covered by such panels account for more than 10% of paediatric deaths, according to one clinical summary. Professional guidance in the United States has moved toward offering carrier screening to anyone planning a pregnancy, rather than only to those with a known family history or particular ancestry. Results can also be relevant to relatives, who may share the same risk. Carrier screening detects only the variants included in a given panel, so a negative result does not exclude all possible risk.

Polygenic and genomic risk scores

Polygenic risk scores (PRS) combine the small effects of many variants across the genome into a single number. Unlike rare, highly penetrant mutations, a PRS reflects a continuous liability to disease rather than a yes-or-no finding. A central difficulty is that a PRS usually expresses relative risk within a group, not an absolute probability for a given individual. A low percentile, for example, typically says little about absolute lifetime risk.

Predictive gains in clinical settings have been modest. In one study of young and midlife adults, adding a PRS did not meaningfully improve discrimination beyond traditional risk factors for coronary heart disease. Accuracy also falls when a score is applied to populations that were underrepresented in the original data. European-ancestry individuals often make up more than 80% of such datasets, and performance tends to be lower in people of African or other non-European ancestry. For these reasons, guidance generally advises against using PRS as a standalone test, and recommends interpreting them alongside clinical risk factors and monogenic testing. Commercial polygenic embryo screening for complex traits has drawn criticism from professional bodies on the grounds of limited predictive reliability.

Ethical concerns

Genetic information is distinctive because it is lifelong, shared among relatives, and can reveal risks that the person tested did not seek. This raises questions about informed consent, especially where newborn screening proceeds by default and parents may not be asked explicitly, and where incidental findings arise. The retention and reuse of stored blood spots or sequence data also raise questions of privacy and data protection. In the United States, federal law prohibits discrimination in health insurance and employment on the basis of genetic information, but it does not cover life, disability or long-term care insurance, which leaves gaps in protection. Equity is an additional concern: if risk models are accurate mainly for populations of European ancestry, their benefits may be unevenly distributed.

Social determinants and health equity

The WHO describes social determinants of health as the conditions in which people are born, grow, live, work and age, together with the systems that respond to illness social determinants The social determinants of health are the circumstances in which people are born, grow up, live, work and age, and the systems put in place to deal with illness. Behind those circumstances sit wider forces, and the WHO names economics, social policy and politics among them These circumstances are in turn shaped by a wider set of forces: economics, social policies, and politics.

Income, education, housing and food as risk factors

The main social determinants of disease risk are income, education, housing, food security and employment. Their effects run through several pathways. Low income reduces access to healthcare and nutritious food and increases hardship. Hardship causes stress which in turn promotes unhealthy coping mechanisms such as substance abuse and overeating of unhealthy foods. The WHO also separates structural determinants, which concern how money, power and resources are distributed, from intermediary determinants, which include employment and working conditions, housing, transportation, and psychosocial conditions. In this model the structural factors act as the root causes of the intermediary ones structural determinants are understood as the root causes of the intermediary determinants.

Health outcomes also vary along a continuous gradient rather than splitting into two groups. At all levels of income, health and illness follow a social gradient: the lower the socioeconomic position, the worse the health. The social gradient in health therefore affects people across the whole distribution, not only those at the bottom. People who have limited access to quality housing, education, social protection and job opportunities have a higher risk of illness and death.

Structural interventions as preventive measures

Because these determinants are upstream, structural interventions such as income support and housing policy count as preventive measures, even though they are not clinical. Evidence on cash transfers is the most extensive. A systematic review concluded that cash transfers increase the consumption of diverse foods, improve the use of health services, and increase school attendance. In HIV prevention, a meta-analysis found that receiving a cash transfer was associated with lowered HIV incidence among individuals who had to meet health-care conditionalities, while no significant effect was observed for HIV testing or antiretroviral therapy adherence. The authors rated the strength of this evidence as moderate The strength of available evidence can be classified as moderate.

The effects of cash transfers are not uniform across outcomes. A review of adolescent contraception found that cash transfer interventions are generally ineffective in raising levels of contraceptive use. However, cash transfer interventions did reduce levels of early pregnancy. The same review noted that there was suggestive evidence that conditional, but not unconditional, cash transfers reduce levels of early childbearing.

Housing-led renovation has also been evaluated. A quasi-experimental study in Glasgow found that investment in housing-led renewal was allocated according to population need and this led to modest reductions in area-based inequalities in health after five years. The authors also flagged a risk of selection bias, which is a reminder that non-randomised evaluations of such programmes need careful interpretation.

Proportionate universalism and unequal access to prevention

Screening and vaccination are offered to whole populations, yet uptake and benefit often follow the same social gradient as other health outcomes. The mechanisms include cost, distance to services, opening hours, health literacy and mistrust of services. Targeting only the most deprived groups is one response, but the Marmot Review argued against it. In its account, it is not sufficient just to focus on the bottom 10 per cent because there are poorer outcomes all the way down from the top. The alternative it proposed is universal action ... but with a scale and intensity that is proportionate to the level of disadvantage. In practice this means that a universal screening or immunization programme receives additional outreach, funding or follow-up in proportion to local need.

The principle has been influential but is applied unevenly. A scoping review found that it had a great resonance but does not seem to have been widely applied and no guidelines exist on how to implement it.

Measuring inequalities in prevention coverage

Assessing equity requires disaggregated data. Coverage of immunization, screening and other preventive services is usually reported by wealth quintile, education level, residence (urban or rural), sex, ethnicity and region, and the gap between the most and least advantaged groups is calculated in both absolute and relative terms. A concentration index summarises the whole socioeconomic distribution rather than comparing two groups alone. Aggregate national averages can conceal large internal gaps, so monitoring systems that disaggregate by social group are a precondition for identifying where proportionate effort is needed.

Policy, legislation and regulation

Legislation gives prevention its enforceable form. When a health goal depends on the behaviour of millions of people, a legal rule can reach far more people than voluntary advice, and it can set a common standard across producers, schools and workplaces. The instruments below recur across countries, and their evidence base differs considerably.

Legal instruments

Compulsory school vaccination is among the oldest preventive laws. Many jurisdictions make enrolment conditional on proof of immunization, usually with medical exemptions and, in some places, religious or philosophical ones. The breadth of those exemptions is itself a recurring policy dispute, because pockets of unvaccinated children can allow outbreaks of diseases such as measles to re-emerge.

Food labelling requires manufacturers to disclose nutrient content, allergens or health messages, and it works mainly by shaping purchasing choices rather than by restricting sales. Tobacco advertising restrictions aim to reduce exposure and the uptake of smoking, particularly among young people. The World Health Organization's tobacco control treaty, the WHO Framework Convention on Tobacco Control, requires parties to introduce a comprehensive ban on advertising, promotion and sponsorship. Its implementation guidance holds that partial bans have limited effect on consumption. Australia was the first country to sell cigarettes in standardised packaging with large graphic health warnings, from December 2012.

Population-wide fortification

Fortification adds a nutrient to a staple food or to drinking water, so that people receive it without individual action. Community water fluoridation began in Grand Rapids, Michigan, on 25 January 1945; the city was paired with Muskegon as a control. Across several paired-city trials, caries among children fell by roughly 50–70% over 13–15 years in fluoridated communities, and the U.S. Public Health Service recommended fluoridation in 1962. The CDC regards it as one of the greatest public health achievements of the twentieth century. Fluoridation remains contested on grounds of safety, dental fluorosis and individual choice, and the controversy has shaped how it is adopted in each jurisdiction.

Salt iodisation follows the same logic. Iodine is added to salt to prevent iodine deficiency disorders, including goitre and impaired neurodevelopment in children, and many countries mandate it. Folic acid added to cereal flour similarly targets neural tube defects. Such measures are cheap per person, but they require a regulated supply chain and monitoring of urinary iodine or population biomarkers to confirm coverage.

Taxation of health-harming products

Taxes raise the price of a product and reduce its use. Tobacco taxation has the strongest evidence base among these measures. Sugar-sweetened beverage (SSB) taxes have spread more recently: the World Health Organization has recommended raising retail prices by at least 20%, and SSB taxes were in force in more than 40 countries covering over 2 billion people by the time of a 2020 World Bank review. A 2023 meta-analysis found that prices rose by most of the tax (about 82% pass-through) and that sales fell with a price elasticity near −1.59. Effects on measured consumption were less precise and not statistically significant in pooled estimates, partly because consumption surveys are noisy. Tax design matters: city-level taxes can be undermined when shoppers buy across the boundary, and the regressive nature of such taxes, which fall more heavily on lower-income households, is a continuing concern in economic analyses. Mexico and the United Kingdom are frequently cited examples of national SSB taxes, and both are widely studied in the economics of prevention.

Implementation gaps and evaluation

The gap between adopted law and effective practice is substantial. A review of the first decade of the FCTC found that implementation was highest for smoke-free laws, health warnings, education campaigns and youth access rules, and lowest for measures against industry interference, product-content regulation and alternative livelihoods for growers. In the WHO European Region, only three countries had banned all forms of indirect advertising, and none had banned all international forms. Tobacco companies have responded with point-of-sale displays, brand stretching, product placement and legal challenges. Many countries were not on track toward the WHO target of a 30% relative reduction in adult tobacco use by 2025.

Evaluation is complicated by the fact that a policy is rarely introduced under controlled conditions. Researchers use natural experiments, comparison regions and difference-in-differences designs, and they must account for confounding by concurrent interventions and price changes. Evidence strength varies: a review of the FCTC found the strongest evidence for smoke-free and tobacco taxation policies, but only limited evidence for advertising restrictions, while WHO guidance describes comprehensive bans as reducing uptake. Knowledge gaps remain on the effects of tobacco control by gender and among disadvantaged groups. Policy effectiveness is therefore judged not only by whether a law exists, but by its comprehensiveness, enforcement and the social determinants that shape who benefits.

Health systems and service delivery

Most preventive services reach people through primary health care, which is generally treated as the main platform for them. WHO describes PHC as a whole-of-society approach that begins as early as possible and runs from health promotion and disease prevention through to treatment, rehabilitation and palliative care, delivered close to people's everyday environments. The WHO identifies five core functions of primary care: first-contact accessibility, continuity of care, coordinated integration of services, comprehensive access to a full range of services, and people-centred care. WHO has also estimated that primary care can deliver over 90% of essential health services, and that about 75% of the projected health gains from the Sustainable Development Goals could be achieved through PHC.

Measuring preventive activity inside primary care remains difficult. In OECD countries, prevention services and home visits by general practitioners (GPs) and nurses make up a smaller proportion of spending on PHC, although services related to prevention activities may often be hard to distinguish from general outpatient consultations. Comparison is further limited because international comparisons of what is spent on PHC have to date been largely absent due to the lack of a commonly accepted definition and an appropriate data collection framework.

The dependence of screening on the rest of the system is one of the most important constraints. Primary prevention, such as immunization, can be run without first strengthening other health services, but this is not the case for secondary prevention. A screening test that detects abnormalities has limited value, and may even harm the patient, if abnormalities cannot be promptly corrected or treated through services from other parts of the health care system. Effective programmes therefore depend on diagnostic capacity, specialist referral, treatment and recall systems that bring people back for follow-up, not only on the screening test itself.

The workforce required for this chain is under strain. WHO's 2025 forecast puts the global shortfall at 11.1 million health workers by 2030, and while the nursing workforce has grown to almost 30 million worldwide, inequalities between countries are a barrier to achieving universal health coverage. Earlier estimates differ because of methodology. The 2016 WHO workforce strategy projected a global shortage of 18 million health workers by 2030, while a 2022 reassessment using newer national data estimated a revised global health workforce shortage of 15 million health workers in 2020 decreasing to 10 million health workers by 2030. In the WHO African Region, analysts attribute persistent gaps to weak HWF planning and constrained fiscal space for health, among other factors, which has produced underinvestment, frontline shortages and unemployment of trained workers.

Financing is the other structural constraint. WHO estimates that achieving the targets for PHC requires an additional investment of around US$ 200 to US$ 328 billion a year for a more comprehensive package of health services. Households carry much of the cost where services are not pre-funded: over 1.6 billion people worldwide were at risk of being pushed into poverty or further impoverished due to out-of-pocket health spending of 10% or more of their household budget in 2022. WHO's recommended response is to reduce out-of-pocket spending, expand essential primary and noncommunicable disease services, and strengthen publicly funded prepaid coverage. Data systems underpin these decisions. WHO's service coverage monitoring draws on a combination of reported administrative data (from countries), survey-derived estimates (from countries and agencies that conduct surveys such as demographic and health surveys and multiple indicator cluster surveys), and modelled estimates (from WHO technical programmes). Patient records used for surveillance and service planning raise questions of data protection as well.

Universal health coverage sets the framework within which these services are supposed to reach everyone. The service coverage index is a composite index on a scale of 0 to 100 that represents coverage of essential health services, composed of 14 tracer indicators in four broad health areas: reproductive, maternal, newborn and child health; infectious diseases; noncommunicable diseases; and service capacity and access. The global index rose from 54 index points in 2000 to 71 in 2023, but progress has slowed since 2015, and if current trends continue, the global UHC service coverage index will only reach 74 by 2030. The noncommunicable disease subindex is now the lowest, despite their dominance in the global burden of disease. Health systems are also vulnerable to disruption: during emergencies, disruption of essential health services in such situations is a considerable threat to quality because of the diversion of resources including skilled workers, financial resources and leadership, which can interrupt preventive programmes that are slow to rebuild.

Economic evaluation and cost-effectiveness

Economic evaluation asks whether a preventive measure delivers enough health for the resources it consumes. Because budgets are finite, it is the main analytical tool for comparing programmes that compete for the same money. Researchers commonly use quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) as health outcome measures, since they account for both longevity and quality of life. In a cost-effectiveness analysis (CEA), the cost of an option is set against the health it produces, and the result is a ratio of the added cost to the added health gained (see costs and effects of programs and at least one alternative are calculated and presented in a ratio of incremental cost to incremental effect). Such ratios let a screening programme, a vaccine campaign and a treatment programme be expressed in the same currency of health.

The two metrics differ in origin and use. A QALY counts a year of life weighted on a scale where "0" is equivalent to death; "1" represents perfect health. A DALY works in the opposite direction, measuring the gap between a health state and an ideal, and it was originally developed by the World Health Organization (WHO) for the Global Burden of Disease (GBD) Study. A DALY is the sum of years of life lost to premature death and years lived with disability. Their use has also diverged geographically: CEAs using DALYs have tended to focus on lower- and middle-income countries, whereas QALY studies have concentrated in high-income settings. Critics note that the two measures can rank the same intervention differently, so comparisons across them need caution.

Cost-effectiveness thresholds translate these ratios into decisions. The WHO-CHOICE project promoted a rule of thumb in which an intervention costing less than three times the national annual GDP per capita per DALY averted is considered cost-effective, whereas one that costs less than once the national annual GDP per capita is considered highly cost-effective. This rule has been widely criticised. Its origins lie in the 2001 Commission on Macroeconomics and Health, which does not explicitly address cost-effectiveness thresholds; rather, it develops estimates for use in benefit-cost analysis. Analysts also argue that the rule omits any consideration of what is truly affordable, and experts across the world, including the WHO, have discouraged its use. Alternative estimates of the health opportunity cost, derived from cross-country data, suggest thresholds nearer to half of GDP per capita.

Return-on-investment (ROI) arguments are often used alongside CEA, especially for vaccines. Their appeal is that they express benefits in money. One widely cited estimate projected that from 2021 to 2030, every US $1 invested in vaccine programs averted around $20 in healthcare costs, lost caregiver wages and missed work, and lost productivity. When benefits are valued through the value of a statistical life, the same programmes returned about US $52 for every $1 spent from 2021 to 2030. These figures depend heavily on method. Studies that value the same intervention with different approaches can produce very different ratios, and ROI analyses that include productivity or wider societal gains may favour working-age populations. Funding sources also matter: an adult-vaccine analysis that reported returns of up to 19 times initial government investment was commissioned by the International Federation of Pharmaceutical Manufacturers & Associations. A high ROI therefore shows that an intervention is worth considering, but it does not by itself establish that it is the best use of a given budget.

Priority-setting under budget constraints rests on opportunity cost: money spent on one programme is unavailable for another. A generous threshold can approve many interventions, and using this threshold leads to more interventions being recommended as "cost-effective." A stricter threshold may leave out measures that would have been worthwhile, so decision-makers often combine CEA with budget-impact analysis, league tables of interventions ranked by cost per unit of health, and judgements about equity and feasibility. Prevention competes with treatment for resources, and the comparison is not always straightforward, since preventive benefits often accrue years later and to people who are not yet ill.

The economic costs that prevention may avert extend well beyond direct medical spending. Childhood immunization programmes require a significant investment but are estimated to save millions of lives and billions of dollars in healthcare costs, transportation costs, and productivity lost due to illness. Averting illness can also protect households from financial ruin: the economic benefits of immunization are often largest for families in the lowest income quintiles, who face the greatest risk of catastrophic medical expenses. For chronic conditions such as hypertension and diabetes, the avoided costs of long-term treatment, lost employment and premature death accumulate over decades, which makes the economic case for prevention depend heavily on the time horizon and discount rate chosen in the model.

Global programmes and international cooperation

Coordinating bodies and shared strategies

Global immunization is coordinated through a partnership in which the World Health Organization (WHO) and UNICEF work with Gavi and other partners on the Immunization Agenda 2030 (IA2030), a strategy endorsed in 2020 whose aim is to bring every country and partner toward common immunization goals. IA2030 is organised around three impact goals: reducing mortality and morbidity from vaccine-preventable diseases across the life course, ensuring that everyone is protected regardless of location, age or income, and strengthening immunization within primary health care as a route toward universal health coverage. Its headline benchmarks for 2030 include 90% coverage with essential childhood and adolescent vaccines and a halving of the number of children who receive no vaccines at all.

UNICEF's own roadmap for 2022–2030 translates these aims into three operational priorities: catching up children whose vaccinations were interrupted during the COVID-19 pandemic, widening equitable access to existing and new vaccines, and strengthening programmes so they can sustain full vaccination within essential primary health care. The follow-up "Big Catch-Up" initiative, launched in 2023, rests on the same logic, with three pillars: catch-up, restoration of coverage to at least 2019 levels, and long-term strengthening of programmes so that fewer children in each new birth cohort are missed.

National immunization programmes carry out these strategies on the ground. They set national schedules, procure and distribute products, train vaccinators and run surveillance. Their performance is sensitive to domestic political and financial commitment: Brazil's National Immunization Programme, which has operated for nearly five decades, saw its coverage fall during the COVID-19 pandemic, illustrating how a national system can lose ground when service delivery is disrupted.

Smallpox eradication

Smallpox is the only human disease that has been eradicated. On 8 May 1980 the 33rd World Health Assembly declared that the world and its peoples had won freedom from the disease, which had caused large numbers of deaths and disfigurement for millennia. The last naturally occurring case was recorded in Somalia in October 1977. The effort had its origins in a Soviet proposal put to the World Health Assembly in 1958, but the funds needed for mass vaccination in endemic countries were not placed in the regular WHO budget until 1966, and the intensified campaign began in January 1967.

The strategy changed during the campaign. Mass vaccination was used first, but it proved less effective in densely populated areas, where a surveillance-containment approach, which identified cases and vaccinated their contacts, became the decisive tool. The programme cost roughly US$300 million, about two-thirds of which was financed by the endemic countries themselves. Its legacy is frequently cited as proof that a coordinated international programme can remove a pathogen entirely, though the eradication was also the product of technological advances such as freeze-dried vaccine production in several countries.

The polio eradication campaign

The Global Polio Eradication Initiative (GPEI), launched in 1988 by the World Health Assembly, Rotary International and partner agencies, set out to end a disease that then paralysed about 350,000 children a year in more than 125 countries. Wild poliovirus type 2 was declared eradicated in 2015 and type 3 in 2019, and the WHO African Region was certified free of wild poliovirus in 2020. Wild poliovirus type 1 remains endemic only in Afghanistan and Pakistan, where transmission persists in a small number of core reservoirs. Official counts from the GPEI reported 35 cases in Afghanistan in 2026 as of early October, while other sources give different totals for earlier periods, so year-on-year figures should be checked against the most recent GPEI reports.

The current strategy, the Polio Eradication Strategy 2022–2026, has two goals: permanently interrupting wild poliovirus transmission in the two remaining countries, and stopping transmission of circulating vaccine-derived poliovirus type 2, which arises where immunity is low and which has caused outbreaks in non-endemic countries. The GPEI's 2026 action plan envisages that certification of wild poliovirus type 1 eradication could follow in 2028, after at least two years without detection, a timetable that depends on closing gaps in the final reservoirs. Polio remains a public health emergency of international concern under the International Health Regulations, and its Emergency Committee reviews the situation regularly.

Sustainable Development Goals and funding

Immunization and prevention are embedded in Sustainable Development Goal 3, "Good health and well-being." Its targets include ending epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, achieving universal health coverage, and supporting research and development of vaccines and medicines for diseases that affect developing countries. The Sustainable Development Goals thus give prevention a place within broader development targets, rather than treating it as a stand-alone health programme.

Progress is uneven. In 2024, nearly 20 million infants missed at least one dose of DTP-containing vaccine, including 14.3 million zero-dose children who received no vaccine at all, which was roughly four million more than the trajectory needed to stay on course for IA2030. Coverage of pneumococcal conjugate and human papillomavirus vaccines has risen since 2022 but remains well below the 90% target, and the world is not on track to halve the number of zero-dose children. WHO and UNICEF have identified the closing of the funding gap for Gavi's 2026–2030 cycle as a priority, together with immunization in conflict and fragile settings and greater reliance on domestic investment within primary health care. These priorities reflect the disparity in prevention capacity between countries: many of the children who miss vaccines live in lower-income countries or in areas affected by conflict, where health systems and financing are weakest.

Ethical issues and controversies

Prevention programmes often ask individuals to accept an intervention, such as vaccination, screening or a restriction, for the sake of a wider population. This creates a tension between individual autonomy and collective benefit. Mandates, exemptions and informed consent are the main instruments through which societies manage it, and each involves trade-offs. Many school vaccination systems allow medical or religious exemptions, which protects individual choice but can leave clusters of unprotected children, as seen in measles outbreaks in parts of the United States. Consent in preventive care is also complicated because the benefit is usually probabilistic and invisible: a healthy person who accepts a vaccine or screening test is accepting a small present risk in exchange for a reduced chance of harm later. Shared decision-making, in which clinicians present absolute rather than relative risks and patients weigh them against their own values, has become the preferred model in screening. Ethical debate therefore centres on how much coercion is justified, how informed the consent must be, and who bears the cost when individual choices reduce coverage below the level needed for collective protection, as explored in ethics and informed consent.

Vaccine hesitancy is the most visible controversy in this area. The World Health Organization defines it as a delay in accepting or a refusal of vaccines despite the availability of vaccination services, and its expert group describes it as shaped by complacency, convenience and confidence. In 2019 the WHO listed it among its ten threats to global health, after a roughly five-fold global increase in measles cases. Its causes vary by setting. In low-income countries, the main barriers are often access, cost and low education, whereas in high-income countries psychological, social and contextual factors tend to predominate. The modern spread of hesitancy is closely linked to misinformation on social media. The fraudulent 1998 study that linked the MMR vaccine to autism, which was exposed in 2004 and formally retracted in 2010, continues to shape parental fears, and safety scares have disrupted polio, measles and HPV vaccination programmes in several countries. Responses include reminder systems, community engagement and tailored messaging, though the effectiveness of digital interventions has been heterogeneous. This topic is covered in more detail under vaccine hesitancy and vaccines.

Overdiagnosis and medicalisation raise a different ethical problem: screening can cause harm even when it works as intended. Overdiagnosis refers to identifying a condition that would never have caused symptoms or death during a person's lifetime. In prostate cancer, PSA testing finds many slow-growing tumours, and the resulting biopsies, surgery or radiotherapy can cause incontinence, erectile dysfunction and bowel problems. One large UK trial estimated that about one in six cancers found by a single PSA screening invitation were overdiagnosed, and the reduction in prostate cancer deaths was small. Analyses of the European and Finnish trials have similarly suggested that, for every few deaths averted per thousand men, tens of excess diagnoses may occur. Overdiagnosis is also age-dependent: a long-term analysis of the UK CAP trial found that it rises sharply with age, leading researchers to question opportunistic testing in older men. The principle of avoiding harm from excessive intervention therefore requires that screening programmes be judged not only by the cases they detect but by the net balance of benefits and harms, a principle addressed in overdiagnosis and related clinical debates.

Privacy and data protection become pressing when prevention relies on surveillance and digital tools. Notification systems, contact tracing and digital risk prediction collect health status, location and social contact data, which are sensitive by nature. Analysts identify two broad risks: unwanted access by government agencies, including law enforcement, and unwanted access by private actors such as advertisers, as well as the possibility of security breaches that grow as apps collect more data. In the European Union, the General Data Protection Regulation classifies health information as a special category requiring stricter safeguards, whereas in the United States, federal health privacy law applies only to certain healthcare providers and their business associates, leaving many app-collected data outside its scope. Public trust is a practical as well as an ethical matter: privacy concerns were among the main reasons people declined to adopt contact-tracing applications, and in South Korea the publication of identifying details of COVID-19 patients produced stigma and harassment. Accountability, data minimisation and clear limits on use are therefore central to the legitimacy of prevention technologies, as discussed in data privacy and contact tracing.

Emerging challenges and future directions

Antimicrobial resistance

Antimicrobial resistance (AMR) threatens the preventive uses of antibiotics, including antibiotic prophylaxis before surgery and after exposures, because a prophylactic drug is only useful while the target organisms remain susceptible. The most detailed global estimate, the GRAM study published in The Lancet, found that in 2021 4·71 million deaths were associated with bacterial AMR, including 1·14 million deaths attributable to bacterial AMR. Its forecasts suggest that an estimated 1·91 million deaths attributable to AMR and 8·22 million deaths associated with AMR could occur globally in 2050. The burden is shifting by age: deaths among children under five fell by half between 1990 and 2021, while deaths among people aged 70 and older rose by more than 80% over the same period.

For prevention, this means that infection control, antimicrobial stewardship and vaccination carry more weight, because each reduces the need for antibiotics that may no longer work. Resistance also weakens the protection that chemoprophylaxis provides to vulnerable groups, so prevention strategies that depend on a narrow set of drugs become less reliable over time.

Climate change and vector-borne disease

Climate change is altering the geography and seasonality of diseases carried by insects and other animals. Rising temperatures, the frequency of extreme weather events, and uncontrolled urbanization have increased the incidence of diseases such as dengue, Zika, chikungunya, malaria, and Lyme disease, particularly in regions with limited infrastructure. Dengue illustrates the pattern: climate drivers have broadly similar effects on the transmission of malaria and dengue, yet malaria has declined since the mid-twentieth century while dengue has expanded rapidly. The divergence reflects non-climatic factors, including long-standing malaria control and the differing effect of urbanization on the two mosquito genera (the long history of effective malaria control interventions and the differential effect of urbanization on malaria and dengue mosquito vectors).

Attribution remains contested. A systematic review of mosquito range expansions found that most expansions were linked to human-aided dispersal (e.g., trade, travel), land-use changes, and urbanization, and that fewer than 10% performed statistical tests of the role of climate. Projections are nonetheless large: a 2022 study in The Lancet Planetary Health estimated that an additional 4.7 billion people may be at risk of the vector-borne diseases malaria and dengue by 2070. Vulnerability is also social. In the Andes, outbreaks above 2000 metres have occurred in areas where poverty, deforestation, and limited access to health services magnify the impact and slow the response. Preventive responses identified in the literature include enhanced surveillance, early warning systems, predictive models and enhanced vector control.

Digital health tools and AI-based risk prediction

Machine-learning models are increasingly proposed for identifying people at high risk, but their validation lags behind their development. In a systematic review of cardiovascular risk models, of 486 models, 380 were development models and 106 were external validation models, and no independent external validations were found in this field. A separate review of AI studies in cardiovascular prediction reported a lack of external validation (20% of models) and lack of clinical impact studies (0%).

Performance also varies across populations. An AI model for mammography-based breast cancer risk, developed in European cohorts, reached an area under the curve of 0.68 in an American screening cohort, compared with 0.73 in the European validation. Its performance was similar for White and Black women, but the authors still called for further testing of bias and generalizability. Researchers have therefore argued for recurring local validation rather than a single external validation, because a model that performs well in one setting may not transfer to another. Dementia risk models face similar requirements: they need real-world testing, and their clinical impact and cost-effectiveness must be measured, especially in low- and middle-income countries.

Evidence gaps and implementation science

Many questions about emerging threats remain open. A systematic review of mosquito range shifts described climate-driven range change as an important scientific evidence gap, and attribution studies that link climate change quantitatively to vector-borne disease burden are few. Strategies for adapting to climate-driven transmission have received limited attention in the reviews themselves, with few reviews explicitly addressing the implementation of adaptation strategies.

These gaps have driven the growth of implementation science, which studies how effective interventions are delivered in routine settings, including cost, staffing, data systems and equity. Its focus reflects a recurring finding that an intervention proven in trials often performs less well when scaled up. Replicability concerns have been raised across several research fields, and this has strengthened calls for pre-registered evaluation, external testing and the measurement of real-world outcomes before preventive tools are adopted widely.

References

1. A Brief History of Vaccinationwho.int
2. The history of the smallpox vaccine - ScienceDirectsciencedirect.com
3. First Smallpox Vaccinationebsco.com
4. Edward Jennerbritannica.com
5. The White Lie at the Heart of Vaccine Historymcgill.ca
6. Germ theory's key 19th century figuresen.wikipedia.org
7. John Snow: Cholera & the Broad Street pumplondonmuseum.org.uk
8. John Snow and the 1854 cholera outbreakyourgenome.org
9. Pioneers in infection control: John Snow, Henry Whitehead, the Broad Street pump, and the beginnings of geographical epidemiology - ScienceDirectsciencedirect.com
10. Smallpox Vaccine: The Good, the Bad, and the Uglyclinmedres.org
11. Ii-key/antigenic epitope hybrid peptide vaccinesimage-ppubs.uspto.gov
12. John Snow's legacy: epidemiology without borders - ScienceDirectsciencedirect.com
13. 1854 Broad Street cholera outbreaken.wikipedia.org
14. Beyond the myths: Novel findings for old paradigms in the history of the smallpox vaccinencbi.nlm.nih.gov
15. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
16. Chapter 4 Basic Concepts in Prevention and Health Promotionphprimer.afmc.ca
17. Preventive medicine - Knowledge @ AMBOSSamboss.com
18. Disease Prevention - Stats - Medbullets Step 2/3step2.medbullets.com
19. Primary, secondary and tertiary preventioniwh.on.ca
20. What Is Primary, Secondary, and Tertiary Prevention? - ScienceInsightsscienceinsights.org
21. Understanding Levels of Disease Preventioneverlywell.com
22. Quaternary preventionen.wikipedia.org
23. Quaternary prevention: reviewing the concept: Quaternary prevention aims to protect patients from medical harmncbi.nlm.nih.gov
24. Quaternary Prevention: Is this Concept Relevant to Public Health? A Bibliometric and Descriptive Content Analysismedrxiv.org
25. Quaternary prevention: Preventing... : Journal of Dr. NTR University of Health Sciencesjournals.lww.com
26. Prevention Strategiesstatpearls.com
27. Medical overuse and quaternary prevention in primary care – A qualitative study with general practitionersncbi.nlm.nih.gov
28. Bradford Hill criteriaen.wikipedia.org
29. Assessing causality in epidemiology: revisiting Bradford Hill to incorporate developments in causal thinking - PMCpmc.ncbi.nlm.nih.gov
30. Frontiersfrontiersin.org
31. Leveraging specificity for causal inference in observational studiesarxiv.org
32. Thesis 8 Conceptual Framework Leavell and Clark s (1965 ...digitalcollections.lrc.usuhs.edu
33. Natural History of Diseases & Levels of Prevention.slideshare.net
34. Vaccine Types UPSC: Live, Inactivated, mRNA, Vector, DNA Comparedanantamias.com
35. Tell Me More: Vaccinespublichealthontario.ca
36. Vaccine typesebsco.com
37. What Kinds of Vaccines Exist, and How Do They Work to Create Immunity Against Disease? - Immunize Coloradoimmunizecolorado.org
38. How Herd Immunity Workshistoryofvaccines.org
39. Herd immunity and COVID-19: What you need to know - Mayo Clinicmayoclinic.org
40. Exacerbation of measles mortality by vaccine hesitancy worldwide - The Lancet Global Healththelancet.com
41. Are the Objectives Proposed by the WHO for Routine Measles Vaccination Coverage and Population Measles Immunity Sufficient to Achieve Measles Elimination from Europe?ncbi.nlm.nih.gov
42. Vaccination Coverage for Routine Vaccines and Herd Immunity Levels against Measles and Pertussis in the World in 2019ncbi.nlm.nih.gov
43. Vaccination and Immunization Statistics - UNICEF DATAdata.unicef.org
44. Latest Global Immunization Coverage Estimates Illustrate Gaps in Vaccine Accesspublichealth.jhu.edu
45. wuenic-progress-and-challenges.pdfcdn.who.int
46. Covering measles in 2026: Updated data, guidance and reliable sourceshealthjournalism.org
47. Different Types of Vaccineshistoryofvaccines.org
48. Types of vaccinevaccineknowledge.ox.ac.uk
49. Immunization: global childhood vaccination coverage rises despite conflict and hesitancyunicef.ch
50. Summary of a systematic review on optimal timing for preoperative surgical antibiotic prophylaxis - Global Guidelines for the Prevention of Surgical Site Infection - NCBI Bookshelfncbi.nlm.nih.gov
51. Timing of Surgical Antibiotic Prophylaxis and the Risk of Surgical Site Infectionjamanetwork.com
52. Antibiotic Prophylaxis to Prevent Surgical Site Infectionsaafp.org
53. Seasonal Malaria Chemopreventiongivewell.org
54. Seasonal malaria chemoprevention: successes and missed opportunitiesncbi.nlm.nih.gov
55. Systematic Review and Meta-Analysis of Seasonal Malaria Chemoprevention in: The American Journal of Tropical Medicine and Hygiene Volume 110 Issue 1 (2024)ajtmh.org
56. Status and prospects of seasonal malaria chemoprevention among children in Sahelian countries: A systematic review and meta-analysisjournals.plos.org
57. Effect of seasonal malaria chemoprevention in children between 5 and 9 years old in Kita and Bafoulabe districts, Mali - ScienceDirectsciencedirect.com
58. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations - PMCpmc.ncbi.nlm.nih.gov
59. Trajectories of Adherence to Oral Pre-exposure Prophylaxis and Risks of HIV and Sexually Transmitted Infectionsacademic.oup.com
60. A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?ncbi.nlm.nih.gov
61. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Forcejamanetwork.com
62. Core Concepts - HIV Preexposure Prophylaxis (PrEP) - Prevention of HIV - National HIV Curriculumhiv.uw.edu
63. Wilson and Jungner Revisited: Are Screening Criteria Fit for the 21st Century?ncbi.nlm.nih.gov
64. Half a Century of Wilson & Jungner: ...wellcomeopenresearch.org
65. Screening Criteria for a Medical Screening Programmegp-training.net
66. (PDF) The Wilson and Jungner principles of screening and genetic testingresearchgate.net
67. Consolidated principles for screening based on a systematic review and consensus processcmaj.ca
68. Lead-Time Bias vs Length-Time Bias — CASRAIcasrai.org
69. Methodologic Issues in the Evaluation of Early Detection Programs - Holland-Frei Cancer Medicine - NCBI Bookshelfncbi.nlm.nih.gov
70. The screening mammography paradox: better when found, perhaps better not to findncbi.nlm.nih.gov
71. Cancer overdiagnosis: A challenge in the era of screening - PMCpmc.ncbi.nlm.nih.gov
72. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosisnature.com
73. Ottawa charter for health promotionslideshare.net
74. Mixed evidence shows some impact of mass media campaigns promoting tobacco control, physical activity and sexual healthevidence.nihr.ac.uk
75. Mass media to communicate public health messages in six health topic areas: a systematic review and other reviews of the evidence - NCBI Bookshelfncbi.nlm.nih.gov
76. Behavior Change Models Compared: 16 Frameworksthebehavioralscientist.com
77. Sentience Institutesentienceinstitute.org
78. Ottawa Charter for Health Promotion, 1986 Health Promotionnaspa.org
79. Health Promotionwho.int
80. Foundations of Health Promotion 1 FOCUS ON Foundations of Health Promotionpublichealthontario.ca
81. Review began 06/12/2024 Review ended 06/19/2024 Published 06/25/2024cureus.com
82. Part 7- Social Science Behavior Theories and Modelssocialscienceshealth.pressbooks.sunycreate.cloud
83. Theories and models of health behaviorfiveable.me
84. Scientific summary - Mass media to communicate public health messages in six health topic areas: a systematic review and other reviews of the evidence - NCBI Bookshelfncbi.nlm.nih.gov
85. Settings, populations, and time: a conceptual framework for public health interventionsncbi.nlm.nih.gov
86. ‘Best buys’ and other recommended interventions for theiris.who.int
87. "Best buys" for the prevention and control of NCDs - PAHO/WHOpaho.org
88. Health policies to tackle chronic diseases can have positive impacts within 5 yearswho.int
89. Tobacco control efforts protect 6.1 billion peoplepaho.org
90. WHO Report on the Global Tobacco Epidemic, 2025: Warning About the Dangers of Tobaccorepository.gheli.harvard.edu
91. WHO report on the global tobacco epidemic,2025 - IRISiris.who.int
92. Countrywide “best buy” interventions for noncommunicable diseases prevention and control in countries with different level of socioeconomic development - Khaltaev - 2023 - Chronic Diseases and Translational Medicine - Wiley Online Libraryonlinelibrary.wiley.com
93. WHO: Here Are The 16 ‘Best Buys’ To Tackle Non-Communicable Diseasesforbes.com
94. WHO global report on hypertension 2025 - The Lancetthelancet.com
95. WHO releases Global Report on Hypertension 2025 (23 September 2025)communitymedicine4asses.wordpress.com
96. Global report on hypertension 2025: high stakes: turning evidence into actionwho.int
97. WHO / GLOBAL HYPERTENSION REPORTmedia.un.org
98. Launch of the WHO Global Hypertension Report 2025who.int
99. Quick Buys for Long-Term Gains: WHO Identifies 25 Fast-Acting Policies to Reduce the Burden of Non-Communicable Diseases - JA PreventNCDpreventncd.eu
100. Implementation of national action plans on noncommunicable diseases, Bhutan, Cambodia, Indonesia, Philippines, Sri Lanka, Thailand and Viet Namncbi.nlm.nih.gov
101. (PDF) Quick buys for prevention and control of noncommunicable diseasesresearchgate.net
102. Global report on hypertension 2025: High stakes—turning evidence into actionresolvetosavelives.org
103. Drinking-waterwho.int
104. WHO/Shehzad Nooraniwho.int
105. Sanitationwho.int
106. Getty Imageswho.int
107. Household air pollutionwho.int
108. Ambient (Outdoor) Air Pollution (EN0103)undrr.org
109. Road traffic injurieswho.int
110. Road traffic deathswho.int
111. The International Health Regulations: The Governing Framework for Global Health Security - PMCpmc.ncbi.nlm.nih.gov
112. At a glancecdc.gov
113. Restored CDCrestoredcdc.org
114. Use of Revised International Health Regulations during Influenza A (H1N1) Epidemic, 2009 - Volume 15, Number 8—August 2009 - Emerging Infectious Diseases journal - CDCwwwnc.cdc.gov
115. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
116. wwwnc.cdc.govwwwnc.cdc.gov
117. International Health Regulations (IHR) 2005ampeid.org
118. Effective contact tracing for COVID-19: A systematic review - PMCpmc.ncbi.nlm.nih.gov
119. Effective Contact Tracing for COVID-19: A Systematic Reviewmedrxiv.org
120. Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic reviewncbi.nlm.nih.gov
121. Automated and partly automated contact tracing: a systematic review to inform the control of COVID-19 - The Lancet Digital Healththelancet.com
122. Infection prevention and controlwho.int
123. Role of hand hygiene in healthcare-associated infection prevention - Journal of Hospital Infectionjournalofhospitalinfection.com
124. Hand hygiene in health care: 20 years of ongoing advances and perspectives - ScienceDirectsciencedirect.com
125. World Hand Hygiene Day 2022afro.who.int
126. A New Approach to Objectively Evaluate Inherited Metabolic Diseases for Inclusion on Newborn Screening Programmesncbi.nlm.nih.gov
127. Newborn Metabolic Screening Programchop.edu
128. Epidemiology of inherited metabolic disorders in newborn screening: insights from three years of experience in Southern Iranncbi.nlm.nih.gov
129. Application of a Novel Algorithm for Expanding Newborn Screening for Inherited Metabolic Disorders across Europencbi.nlm.nih.gov
130. Carrier screening for family planning - Mayo Clinic Health Systemmayoclinichealthsystem.org
131. How Carrier Screening Impacts Family Planning Decisionsraveco.com
132. Mayo Clinic Q and A: Understanding carrier screening for family planning - Mayo Clinic News Networknewsnetwork.mayoclinic.org
133. What to Know About Genetic Testing and Carrier Screening Before Pregnancyctcoastalobgyn.com
134. Pitfalls of predicting age‐related traits by polygenic risk scoresncbi.nlm.nih.gov
135. Translating polygenic risk scores for clinical use by estimating the confidence bounds of risk predictionncbi.nlm.nih.gov
136. The clinical application of polygenic risk scores: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG) - Genetics in Medicinegimjournal.org
137. Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adultsahajournals.org
138. Polygenic risk scores in pharmacogenomics: methodological challenges, current applications, and perspectives for clinical implementation - PMCpmc.ncbi.nlm.nih.gov
139. Polygenic risk scores in clinical applicationspmc.ncbi.nlm.nih.gov
140. Polygenic risk scores: Navigating the future of precision medicine through economic, ethical, and scientific advancements: iSciencecell.com
141. Social determinants of health: Key conceptswho.int
142. Social Determinants of Health (SDOH)catalyst.nejm.org
143. Social Determinants of Health - PAHO/WHOpaho.org
144. Social determinants of healthwho.int
145. Cash transfers for HIV prevention: A systematic reviewncbi.nlm.nih.gov
146. The effects of cash transfer programmes on HIV/AIDS prevention and care outcomes: a systematic review and meta-analysis of intervention studies - ScienceDirectsciencedirect.com
147. Can cash transfer interventions increase contraceptive use and reduce adolescent birth and pregnancy in low and middle income countries? A systematic review and meta-analysisncbi.nlm.nih.gov
148. Proportionate universalism in practice? A quasi-experimental study (GoWell) of a UK neighbourhood renewal programme's impact on health inequalities - ScienceDirectsciencedirect.com
149. Marmot Review reportlocal.gov.uk
150. (PDF) Theoretical and practical challenges of proportionate universalism: A reviewresearchgate.net
151. Impact of the WHO FCTC over the first decade: a global evidence review prepared for the Impact Assessment Expert Group - PMCpmc.ncbi.nlm.nih.gov
152. WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL Guidelines for implementationfctc.who.int
153. banning tobacco advertising sponsorship and promotionwho.int
154. WHO advocates total ban on tobacco advertising, promotion and sponsorshipwho.int
155. Timeline for Community Water Fluoridationcdc.gov
156. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
157. www.cdc.govcdc.gov
158. Fluoride fact sheet Englishminneapolismn.gov
159. TAXES ON SUGAR- SWEETENED BEVERAGES: International Evidence and Experiencesthedocs.worldbank.org
160. Outcomes Following Taxation of Sugar-Sweetened Beverages: A Systematic Review and Meta-analysisjamanetwork.com
161. Fiscal Policy for Health: Sugar-Sweetened Beverage Tax Design and Soft Drink Consumption Across Geographies, 2010–2024 - PMCpmc.ncbi.nlm.nih.gov
162. NBER WORKING PAPER SERIESnber.org
163. Evaluating the Evidence on Beverage Taxes: Implications for Public Health and Health Equityjamanetwork.com
164. Primary careen.wikipedia.org
165. Models of global primary care post-2030 - ScienceDirectsciencedirect.com
166. Primary health carewho.int
167. Health expenditure on prevention and primary healthcare: Health at a Glance 2025oecd.org
168. Health promotion and disease prevention through population-based interventions, including action to address social determinants and health inequityemro.who.int
169. World Health Organization (WHO) on X: "⚠️ 2025: WHO forecasts a global shortfall of 11.1 million health workers by 2030. While the nursing workforce has grown to almost 30 million worldwide, inequalities between countries are a barrier to achieving universal health coverage. Strengthening and supporting the nursing https://t.co/fbx8bbS4wu" / Xx.com
170. The global health workforce stock and distribution in 2020 and ...nursing.jhu.edu
171. Projected health workforce requirements and shortage for addressing the disease burden in the WHO Africa Region, 2022–2030: a needs-based modelling studyncbi.nlm.nih.gov
172. Universal health coverage global monitoring report 2023who.int
173. Tracking Universal Health Coverage (UHC): 2025 Global Monitoring Reportworldbank.org
174. Quality in primary health carewho.int
175. Universal health coverage (UHC)who.int
176. Comparing the cost-per-QALYs gained and cost-per-DALYs averted literaturesncbi.nlm.nih.gov
177. A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Avertedjournals.plos.org
178. Global Health CEA - The DALYghcearegistry.org
179. Cost Utility Analysis - an overviewsciencedirect.com
180. Thresholds for the cost–effectiveness of interventions: alternative approachesncbi.nlm.nih.gov
181. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholdsacademic.oup.com
182. What next after GDP-based cost-effectiveness thresholds?ncbi.nlm.nih.gov
183. The Value of Vaccines: Investments in Immunization Yield High Returnsimmunizationevidence.org
184. Adult vaccines offer substantial return on investment when considering full value, report sayscidrap.umn.edu
185. The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review - PMCpmc.ncbi.nlm.nih.gov
186. Page 1 Summary of Key Evidence Related to Economic Benefitspublichealth.jhu.edu
187. Part V: Cost-Effectiveness Analysis Outcomes in Natural Units:cdc.gov
188. Gates Open Research Article: What next after GDP-based cost-effectiveness thresholds?.gatesopenresearch.org
189. The global return-on-investment of COVID-19 vaccines in the first year of the vaccination programmemedrxiv.org
190. IMMUNIZATION AGENDA 2030 MID-TERM REVIEW NOVEMBER 2025cdn.who.int
191. UNICEF IMMUNIZATION ROADMAP TO 2030unicef.org
192. Immunization Agenda 2030apps.who.int
193. 1 IMPLEMENTING THE IMMUNIZATION AGENDA 2030:cdn.who.int
194. Immunization Agenda 2030 and Brazil’s challengesncbi.nlm.nih.gov
195. Global childhood vaccination coverage holds steady, yet over 14 million infants remain unvaccinatedwho.int
196. Five Takeaways and Next Steps from the Immunization Agenda 2030publichealth.jhu.edu
197. The WHO and the Eradication of Smallpoxorigins.osu.edu
198. Smallpox Eradication - an overviewsciencedirect.com
199. Commemorating Smallpox Eradicationwho.int
200. Smallpox Eradication Programme - SEP (1966-1980)who.int
201. History of smallpox vaccinationwho.int
202. The Triumph of Science: The Incredible Story of Smallpox Eradication - NFIDnfid.org
203. Smallpox Still Haunts Scientists: Results of a Questionnaire-Based Inquiry on the Views of Health Care and Life Science Experts and Students on Preserving the Remaining Variola Virus Stocksncbi.nlm.nih.gov
204. Polio eradication strategy 2022–2026: delivering on a promisewho.int
205. GPEI-Action-Plan-2026.pdfpolioeradication.org
206. Polio This Weekpolioeradication.org
207. Afghanistan reports 4 more wild poliovirus cases, brings 2026 total to 11outbreaknewstoday.substack.com
208. Statement of the Forty-fourth Meeting of the Polio IHR Emergency Committeewho.int
209. Progress Toward Polio Eradication — Worldwide, January 2019–June 2021cdc.gov
210. World Polio Day 2026: Date, Theme, Symptoms & Preventiongeimshospital.com
211. Rotary Club of Campbell River hosting Pumpkins for Polio fundraisercampbellrivermirror.com
212. A systematic literature review to clarify the concept of vaccine hesitancynature.com
213. Vaccine hesitancy is one of the greatest threats to global healthgavi.org
214. WHO Names Vaccine Hesitancy As Top World Threat in 2019usnews.com
215. Vaccine hesitancy: a generation at risk - The Lancet Child & Adolescent Healththelancet.com
216. 11.M. Workshop: Vaccination hesitancy in the Western Balkans and inclusive governancencbi.nlm.nih.gov
217. Vaccine Hesitancyglobalvaccinedatanetwork.org
218. Vaccine Hesitancy Fuels Global Health Crisis Amidst Multidisease Outbreaksajmc.com
219. Prostate Cancer Screening with a PSA Test Leads to Overdiagnosisclpmag.com
220. Risk factors for low‐risk prostate cancer: A retrospective cohort study within the FinRSPC trialncbi.nlm.nih.gov
221. Overdiagnosis and Overtreatment in Prostate Cancerncbi.nlm.nih.gov
222. Recommendation: Prostate Cancer: Screeninguspreventiveservicestaskforce.org
223. Prostate Cancer Screening (PDQ®) - NCIcancer.gov
224. Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age - The ASCO Postascopost.com
225. Digital Contact Tracing and Data Protection Lawcongress.gov
226. Privacy Concerns Multiply as Digital Contact Tracing Spreads: U.S. Tech Industry Takes the Lead as Congress Fails to Act (Privacy)lowenstein.com
227. Privacy and security concerns with passively collected location data for digital contact tracing among U.S. college studentsncbi.nlm.nih.gov
228. The Privacy Concerns of Contact Tracingchicagopolicyreview.org
229. Privacy and Security in Digital Health Contact-Tracing: A Narrative Reviewmdpi.com
230. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 - The Lancetthelancet.com
231. Impact of Climate Change on the Global Dynamics of Vector-Borne Infectious Diseases: A Narrative Reviewncbi.nlm.nih.gov
232. How climate change affects mosquito-borne infectious disease: The different trajectories of malaria and denguescience.org
233. A systematic review of climate-change driven range shifts in mosquito vectorsncbi.nlm.nih.gov
234. How does climate change affect vector-borne diseases?wellcome.org
235. Climate change and the rising threat of vector-borne diseases in the Andes - PMCpmc.ncbi.nlm.nih.gov
236. Charting the evidence for climate change impacts on the global spread of malaria and dengue and adaptive responses: a scoping review of reviewsncbi.nlm.nih.gov
237. Artificial intelligence in the risk prediction models of cardiovascular disease and development of an independent validation screening tool: a systematic reviewbmcmedicine.biomedcentral.com
238. Artificial Intelligence (AI) Models for Cardiovascular ...medrxiv.org
239. A systematic review of climate-change driven range shifts in mosquito vectorsbiorxiv.org
240. The Lancet: More than 39 million deaths from antibiotic-resistant infections estimated between now and 2050, suggests first global analysishealthdata.org
241. External Validation of a Mammography-Derived AI-Based Risk Model in a U.S. Breast Cancer Screening Cohort of White and Black Womenncbi.nlm.nih.gov
242. External Validation of Dementia Risk Prediction Models: Towards evidence‐based implementationncbi.nlm.nih.gov
243. Performance evaluation of predictive AI models to support medical decisions: Overview and guidancearxiv.org
244. Artificial Intelligence-Based Methods for Precision Medicine: Diabetes Risk Predictionarxiv.org